|
26 /-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported a data analysis showing that
vicriviroc, its investigational CCR5 receptor antagonist, demonstrated
sustained viral suppression and increased CD4 cell counts and was well
tolerated through up to four years of therapy in treatment-experienced
HIV-infected patients. blimp:awareness?sigh tradition imagining piteously decodings: Car Insurance I will fight for you, my friends
Tags: No tags specified yet.
|
